FIRDAPSE Patent Expires February 2035, Threatens 70-80% Revenue Decline for Catalyst Pharmaceuticals
Catalyst Pharmaceuticals faces a patent cliff in February 2035 when FIRDAPSE exclusivity ends. Generic competition is projected to erode 70-80% of this revenue stream within two to three years. Investors should monitor earnings impact as the expiration date approaches.
ViaNews Editorial Team (Markets)•